Botswana vs Sri Lanka: Average cost of multi drug-resistant tuberculosis treatment
Botswana
900 constant 2022 US$
in 2024
Sri Lanka
902 constant 2022 US$
in 2024
Botswana rank
53rd
Sri Lanka rank
52nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Botswana
- Sri Lanka
How they compare
Sri Lanka currently reports 902 constant 2022 US$ against 900 constant 2022 US$ in Botswana, a difference of 2 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Botswana ahead.
Botswana ranks 53rd and Sri Lanka ranks 52nd of 92 countries.
Botswana has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Botswana | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,278 constant 2022 US$ | 2,695 constant 2022 US$ | 4,584 constant 2022 US$ | Botswana |
| 2020s | 3,700 constant 2022 US$ | 1,652 constant 2022 US$ | 2,048 constant 2022 US$ | Botswana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Botswana or Sri Lanka?
- Sri Lanka, at 902 constant 2022 US$ against 900 constant 2022 US$ in Botswana as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Botswana and Sri Lanka?
- 2 constant 2022 US$, with Sri Lanka ahead.
- How many years of comparable data are there for Botswana and Sri Lanka?
- 5 years are reported by both, from 2017 to 2024.
- How do Botswana and Sri Lanka rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Botswana ranks 53rd and Sri Lanka ranks 52nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.